Skip to content
NovAccess Global Logo
XSNX 0.17 +0.02 +16.36%
  • Home
  • Our Mission
  • Science & Tech
  • StemVax
  • Team
  • Investors
    • News
    • Publications
    • Press Releases
    • SEC Filings
    • Presentations
    • Contact
Menu
  • Home
  • Our Mission
  • Science & Tech
  • StemVax
  • Team
  • Investors
    • News
    • Publications
    • Press Releases
    • SEC Filings
    • Presentations
    • Contact
NovAccess Global Logo
XSNX 0.17 +0.02 +16.36%
  • Home
  • Our Mission
  • Science & Tech
  • StemVax
  • Team
  • Investors
    • News
    • Publications
    • Press Releases
    • SEC Filings
    • Presentations
    • Contact
Menu
  • Home
  • Our Mission
  • Science & Tech
  • StemVax
  • Team
  • Investors
    • News
    • Publications
    • Press Releases
    • SEC Filings
    • Presentations
    • Contact

Category: Financial Report

Innovest Global financial reports.

NovAccess Global Readies for Development of Novel Immunotherapies for Brain Tumor Patients with pre-IND meeting scheduled with the FDA and Files Form 10-K for Fiscal 2020 and Form 10-Q for FQ1/FQ2, 2021

Revolutionary advances in the  understanding of how our bodies can fight cancer, and how to put that information to use in treating existing tumors. NovAccess Global’s team of experts is working to strengthen the capability of the human body’s defense against cancer.

Youtube Facebook Twitter Linkedin

Privacy Policy

Forward-Looking Statements

Contact Us

  • +1 213-642-9268
  • info@novaccessglobal.com
  • Corporate HQ
  • 8584 E. Washington Street #127 Chagrin Falls, Ohio 44023
  • Research & Development
  • 2265 E. Foothill Blvd, Pasadena, CA 91107

JOIN US

Stay up-to-date with our journey

Facebook Twitter Linkedin

Privacy Policy

Privacy Policy

Forward-Looking Statements